APAP-CYS Protein Adduct Concentrations in Patients With Liver-Directed Therapy Intended to Treat Hepatic Tumors
Status:
Withdrawn
Trial end date:
2021-08-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to provide preliminary data to describe serum
acetaminophen-cysteine protein adduct (APAP-CYS) concentrations following therapeutic doses
of acetaminophen in the setting of non-acetaminophen induced liver injury. This study will
utilize hepatic embolization as a model of hepatic injury.
Phase:
Phase 4
Details
Lead Sponsor:
Denver Health and Hospital Authority
Collaborators:
Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division McNeil Consumer Healthcare Division of McNEIL-PPC, Inc. Rocky Mountain Poison and Drug Center University of Colorado, Denver